# XOLREMDI
> **NDA218709** · New Drug Application · Sponsor: X4 PHARMS · Approved 2024-04-26
## Drug
- **FDA Application Number:** NDA218709
- **Application type:** New Drug Application
- **Brand name:** XOLREMDI
- **Generic name:** MAVORIXAFOR
- **Active ingredients:** MAVORIXAFOR
- **Dosage form:** CAPSULE
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** X4 PHARMS
- **Manufacturer:** X4 Pharmaceuticals, Inc.
- **First approval:** 2024-04-26
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218709)
---
*AI Analytics · CC0 1.0*